Kilitch Drugs (India) share price today

Kilitch Drugs (India) Ltd's share price was ₹208.91 at the close on 4 November 2026. It has been rising for 19 weeks. That is 11.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹128 and ₹242, and at that close it sat 71% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Kilitch Drugs (India) Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 9 weeks in a row.

Over the last 11 years the share price moved +966% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: lowest operating margin in 8 quarters.

1. Lowest operating margin in 8 quarters

   Operating margin was 6.6% in the June 2026 quarter, against 7.6% a year earlier.

For April to June 2026 (the quarter ended 30 June 2026), Kilitch Drugs (India) reported revenue of ₹44.9 crore, up 4.0% from ₹43.1 crore a year earlier, and a profit of ₹1.96 crore, down 13.7% from ₹2.27 crore.

Kilitch Drugs (India) results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 10 June 2024, about January to March 2024; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Kilitch Drugs (India) closed at ₹208.91 on 4 November 2026, up 10.1% from ₹189.75 a year earlier (7 November 2025) and up 129.7% over five years. Its highest weekly close since March 2016 was ₹241.61 on 9 October 2026.

Kilitch Drugs (India) share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Kilitch Drugs (India) closed at ₹208.91, up 3.8% on the week and down 4.4% on the month. Results for April to June 2026: Revenue up 4.0% and profit down 13.7% on a year earlier.

Earlier

• 24 Mar 2026: Bonus issue: 1 new share for every 1 held (ex-date).
• 10 Jun 2024: Kilitch Drugs (India) held its results call for January to March 2024.

Kilitch Drugs (India) has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

Not in its latest year. Kilitch Drugs (India) Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 3 of its last 13 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

On the call for January to March 2024, held on 10 June 2024, Kilitch Drugs (India)'s management spoke about the quarter; the main points are below.

Source: the call transcript.

From the call for January to March 2024, 10 June 2024. The April to June 2026 results are out since, so this part may be out of date until we update it.

Kilitch Drugs (India) is on one of our India lists: Pharma stocks.

Kilitch Drugs (India) Ltd earned ₹2.0 Cr of net profit in the Jun 2026 quarter, −13.7% on the same quarter a year earlier. Full-year FY26 profit was ₹30.0 Cr. That is 4.4% of the quarter's revenue. The same quarter a year earlier earned ₹2.3 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹30.0 Cr (+20.0% on the year before).

Why profit moved: revenue changed +4.0% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +0.5% and revenue +12.3%. Profit is growing slower than sales: rising costs are taking part of the growth.

Kilitch Drugs (India) Ltd reported ₹44.9 Cr of revenue in the Jun 2026 quarter, +4.0% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown 27.3% a year on average. The last full year, FY26, came in at ₹235 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹237 Cr.

FY26 revenue was ₹235 Cr, +18.7% on the year before.

Recent pace: the last four quarters grew +12.3% on average, against 27.3% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +14.0%, against +25.2% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +9.3%, against +65.8% a year (rolling over).

Kilitch Drugs (India) Ltd's operating margin was 6.5% in the Jun 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −19.0% and 16.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −1.0 percentage points on the year while gross margin changed +4.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 58% of Kilitch Drugs (India) Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹24.0 Cr of operating cash against ₹30.0 Cr of profit. After ₹100 Cr of spending on assets, free cash was −₹76.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 58% of profit came in as cash: the cash cycle got 356 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 356 days longer. The next section looks at where the cash is stuck.

Kilitch Drugs (India) Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −11 days in FY26, up from −367 days in FY21. It spent ₹149 Cr on assets over the last 3 years. Customers take 186 days to pay, and stock sits for 33 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹235 Cr, each day of that cycle ties up about ₹0.6 Cr, so roughly −₹7.0 Cr is tied up in the business at any time.

FY26: customers took 186 days to pay and stock sat for 33 days, about 1.1 months of sales sitting as stock, for a full cycle of −11 days, longer than FY21's −367.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 33 days. Customers pay about 186 days after that. Suppliers are paid at 230 days. Together that makes the −11-day cycle.

Spending on assets: ₹149 Cr over the last 3 years, against ₹10.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹140 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Kilitch Drugs (India) Ltd's P/E is 24.3×, near the low end of its own history: it has been lower only 17% of the time. Its usual P/E (the middle reading) is 39.6×, over 8.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.